CLINICAL TRIALS PROFILE FOR VESICARE LS

All Clinical Trials for VESICARE LS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00333112 ↗	A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.	Completed	Astellas Pharma Inc	Phase 4	2006-05-01	A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.
NCT00368706 ↗	A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients	Completed	Astellas Pharma Inc	Phase 3	2006-09-01	To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid
NCT00431041 ↗	Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)	Completed	Astellas Pharma Canada, Inc.	Phase 4	2006-12-01	The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
NCT00431041 ↗	Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)	Completed	Astellas Pharma Inc	Phase 4	2006-12-01	The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
NCT00454740 ↗	Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder	Completed	Astellas Pharma Inc	Phase 3	2004-06-01	To evaluate the efficacy of 5 and10mg solifenacin succinate in patients with urgency who have OAB syndrome (urgency, with or without urge incontinence, usually with frequency and nocturia) and wish to switch from tolterodine tartrate extended release to solifenacin succinate due to lack of sufficient improvement in urgency episodes
NCT00454896 ↗	A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)	Completed	Astellas Pharma Inc	Phase 3	2004-05-01	The purpose is to evaluate the efficacy of 5 and 10mg VESIcare® (solifenacin succinate) in patients with urgency who have overactive bladder syndrome.
NCT00463541 ↗	Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms	Completed	Astellas Pharma Inc	Phase 3	2004-06-01	To evaluate the safety and efficacy of solifenacin succinate in subjects with overactive bladder symptoms (urgency, with or without urge incontinence, usually with frequency and nocturia).

Clinical Trial Conditions for VESICARE LS

Condition Name

Condition Name for VESICARE LS
Intervention	Trials
Overactive Bladder	24
Urinary Bladder, Overactive	15
Urinary Incontinence	6
Urinary Bladder Diseases	4

Condition MeSH

Condition MeSH for VESICARE LS
Intervention	Trials
Urinary Bladder, Overactive	45
Urinary Incontinence	10
Enuresis	10
Urinary Incontinence, Urge	6

Clinical Trial Locations for VESICARE LS

Trials by Country

Trials by Country for VESICARE LS
Location	Trials
United States	330
Canada	31
Germany	18
Hungary	15
United Kingdom	14

Trials by US State

Trials by US State for VESICARE LS
Location	Trials
California	15
Texas	13
Pennsylvania	13
Florida	13
North Carolina	12

Clinical Trial Progress for VESICARE LS

Clinical Trial Phase

Clinical Trial Phase for VESICARE LS
Clinical Trial Phase	Trials
Phase 4	27
Phase 3	15
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for VESICARE LS
Clinical Trial Phase	Trials
Completed	50
Terminated	7
Unknown status	5

Clinical Trial Sponsors for VESICARE LS

Sponsor Name

Sponsor Name for VESICARE LS
Sponsor	Trials
Astellas Pharma Inc	25
Astellas Pharma Europe B.V.	8
Astellas Pharma Korea, Inc.	6

Sponsor Type

Sponsor Type for VESICARE LS
Sponsor	Trials
Industry	52
Other	49
NIH	3